Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.
1. A method of treating a subject with an inflammatory, fibrostenotic, or fibrotic disease or condition, comprising administering to the subject a therapeutically effective amount of a therapeutic agent, provided a presence of a genetic risk variant at rs5745994 comprising a “C” allele at nucleobase position 76 within SEQ ID NO: 1 at a gene locus TNFRSF1B is detected in a biological sample obtained from the subject.
2. The method of claim 1 , wherein a decreased level of Tumor necrosis factor receptor 2 (TNFR2) is detected in a sample obtained from the subject, compared to a reference value obtained from an individual who is not a carrier of the genetic risk variant.
3. The method of claim 1 , wherein a level of ANCA is detected in a biological sample obtained from the subject that is at or above a first threshold level comprising about 100 ELISA units (EU).
4. The method of claim 1 , wherein a level of ANCA is detected in a biological sample obtained from the subject that is lower than a first threshold level comprising about 100 ELISA units (EU) and higher than a second threshold level comprising about 50 EU.
5. The method of claim 4 , wherein the level of ANCA and the presence of the risk variant is indicative that the subject is non-responsive, or susceptible to non-response, to anti-Tumor Necrosis Factor alpha (TNFα) therapy.
6. The method of claim 4 , wherein the level of ANCA, the presence of the genetic risk variant, and a decreased level of TNFR2 as compared to a reference value obtained from an individual who is not a carrier of the genetic risk variant, detected in the biological sample obtained from the subject is indicative that the subject is nonresponsive, or susceptible to non-response, to anti-TNFα therapy.
7. The method of claim 1 , wherein the presence of the genetic risk variant detected in the biological sample obtained from the subject is indicative that the subject is non-responsive, or susceptible to non-response, to anti-TNFα therapy.
8. The method of claim 1 , wherein a level of ANCA is detected in a biological sample obtained from the subject using an assay comprising an anti-ANCA antibody.
9. The method of claim 1 , wherein the inflammatory, fibrostenotic, or fibrotic disease or condition comprises inflammatory bowel disease (IBD), Crohn's disease (CD), perianal Crohn's disease (pCD), ulcerative colitis (UC), rheumatoid arthritis, multiple sclerosis, psoriasis, chronic colitis, pancreatitis, leukopenia, colonic fibrosis, primary sclerosing cholangitis, progressive systemic sclerosis, chronic asthma, or fibrostenosis of a small and/or large intestine, or a combination thereof.
10. The method of claim 1 , wherein the genetic risk variant is detected by contacting the biological sample obtained from the subject with a nucleic acid molecule comprising a nucleic acid sequence capable of hybridizing to 10 contiguous nucleobases of SEQ ID NO. 1 spanning nucleobase 76 within SEQ ID NO: 1 under standard hybridization conditions.
11. The method of claim 10 , wherein the standard hybridization conditions comprise an annealing temperature between about 30° C. and about 65° C.
12. A method comprising:
(a) assaying to detect in a biological sample obtained from a subject with an inflammatory, fibrostenotic, or fibrotic disease or condition, a level of antineutrophil cytoplasmic antibody (ANCA), a presence of a genetic risk variant comprising a risk allele at rs5745994 comprising a “C” allele at nucleobase position 76 within SEQ ID NO: 1 at a gene locus TNFRSF1B, or a combination thereof;
(b) identifying the subject as being non-responsive to anti-TNFα therapy, or susceptible to non-response to anti-TNFα therapy, provided (i) a level of ANCA that is at or above a first threshold level comprising about 100 ELISA units (EU), or (ii) a level of ANCA that is lower than the first threshold level and above a second threshold level comprising about 50 EU, and the presence of the genetic risk variant, are detected in the biological sample obtained from the subject; and
(c) treating, or prescribing a treatment for, the inflammatory, fibrostenotic, or fibrotic disease or condition in the subject, provided the subject is identified as being non-responsive to anti-TNFα therapy, or susceptible to non-response to anti-TNFα therapy.
13. The method of claim 12 , wherein treating the inflammatory, fibrostenotic, or fibrotic disease or condition in the subject of (c) further comprises administering to the subject a therapeutically effective amount of a therapeutic agent.
14. The method of claim 12 , wherein the inflammatory, fibrostenotic, or fibrotic disease or condition comprises inflammatory bowel disease (IBD), Crohn's disease (CD), perianal Crohn's disease (pCD), ulcerative colitis (UC), rheumatoid arthritis, multiple sclerosis, psoriasis, chronic colitis, pancreatitis, leukopenia, colonic fibrosis, primary sclerosing cholangitis, progressive systemic sclerosis, chronic asthma, or fibrostenosis of a small and/or large intestine, or a combination thereof.
15. The method of claim 12 , further comprising assaying to detect a level of TNFR2, wherein a decrease in TNFR2, compared to a reference value obtained from an individual who is not a carrier of the genetic risk variant, is indicative of non-response to anti-TNFα therapy in the subject.
16. The method of claim 12 , wherein the level of ANCA is detected using an assay comprising an anti-ANCA antibody.
17. The method of claim 16 , where the assay comprises a neutrophil-fixed enzyme-linked immunosorbent assay (neutrophil fixed-ELISA).
18. The method of claim 12 , wherein the genetic risk variant is detected by contacting the sample obtained from the subject with a nucleic acid molecule comprising a nucleic acid sequence capable of hybridizing to 10 contiguous nucleobases of SEQ ID NO. 1 spanning nucleobase 76 within SEQ ID NO: 1 under standard hybridization conditions, wherein the standard hybridization conditions comprise an annealing temperature between about 30° C. and about 65° C.